Exelixis (EXEL) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Exelixis (EXEL) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Exelixis |
13.61 Bn |
12.83 Bn |
590.86 Mn |
31.86% |
| Date | Value |
|---|
| Apr 3, 2026 |
31.86% |
| Jan 2, 2026 |
74.84% |
| Oct 3, 2025 |
64.09% |
| Jul 4, 2025 |
-18.25% |
| Apr 4, 2025 |
327.73% |
| Jan 3, 2025 |
63.55% |
| Sep 27, 2024 |
11,232.66% |
| Jun 28, 2024 |
178.54% |
| Mar 29, 2024 |
-6.77% |
| Dec 29, 2023 |
383.43% |
| Sep 29, 2023 |
-98.58% |
| Jun 30, 2023 |
14.87% |
| Mar 31, 2023 |
-41.63% |
| Dec 30, 2022 |
-131.71% |
| Sep 30, 2022 |
91.63% |
| Jul 1, 2022 |
-26.45% |
| Apr 1, 2022 |
4,183.14% |
| Dec 31, 2021 |
167.74% |
| Oct 1, 2021 |
219.24% |
| Jul 2, 2021 |
43.81% |
